

Key Investor Information

This document provides you with key investor information about this Fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this Fund. You are advised to read it so you can make an informed decision about whether to invest.

HSBC GLOBAL INVESTMENT FUNDS - GLOBAL EQUITY SUSTAINABLE HEALTHCARE

a sub-fund of HSBC Global Investment Funds, (the "UCITS"); managed by HSBC Investment Funds (Luxembourg) S.A.

Class:JDEUR ISIN:LU2430300645

Objectives and Investment Policy

Investment Objective:

The Fund aims to provide long term capital growth and income by investing in a concentrated portfolio of shares of companies that may benefit from increasingly constrained healthcare budgets worldwide, while promoting ESG characteristics.

The Fund promotes ESG characteristics within the meaning of Article 8 of SFDR. More information on HSBC Global Asset Management's responsible investing policies is available at www.assetmanagement. hsbc.com/about-us/responsible-investing/policies.

Investment Policy:

The Fund aims to achieve its investment objective by investing in shares of companies with current or expected revenue exposure to sustainable healthcare products. The Fund's social focus is to improve the affordability of healthcare, aiming to alleviate the budgetary pressures of providing healthcare. Such companies (Healthcare Companies) are determined based on HSBC proprietary analysis including sustainable healthcare scores. The Fund's aims are aligned with goal three of the UN sustainable development goals.


In normal market conditions, the Fund will invest at least 70% of its assets in shares (or securities similar to shares) of Healthcare Companies of any size, that are based in, carry out business activities in, or are listed on a regulated market in, developed and emerging markets.

The Fund will not invest in shares (or securities similar to shares) of companies which have a material exposure, exceeding a revenue exposure threshold (which will not be higher than 30% of the relevant company's total revenue), to specific excluded activities, including but not limited to; genetic manipulations affecting the germline of humans; involvement in the production of controversial weapons and tobacco; and issuers with more than 10% revenue generated from thermal coal extraction or with more than 10% revenue generated from coal-fired power generation. These exclusions are in addition to HSBC's banned weapons policy. Please refer to the Prospectus for further details on sustainable healthcare products and excluded activities.

The Fund may invest up to 40% in China A and China B-shares. For China A-shares, up to 20% through the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect, up to 20% in CAAPs and up to 10% in CAAPs issued by any single issuer. The Fund may invest up to 40% of its asset in shares listed on the ChiNext Board of the Shenzhen Stock Exchange and/or the Science and Technology Innovation Board of the Shanghai Stock Exchange. The Fund may invest in bank deposits, money market instruments and funds for treasury purposes and up to 10% in other funds. The Fund may invest in derivatives and use them for hedging and efficient portfolio management purposes. Derivatives will not be used extensively for investment purposes. Derivatives may also be embedded in other instruments used by the Fund.

- The Fund may enter into securities lending transactions for up to 29% of its assets. However, this is not expected to exceed 25%.
- The reference currency of the Fund is USD. The reference currency of this share class is EUR.
- The Fund is actively managed and does not track a benchmark. The reference benchmark for the Fund is MSCI World Health Care Index
- The Investment Advisor will use its discretion to invest in securities not included in the reference benchmark based on active investment management strategies and specific investment opportunities. It is foreseen that a significant percentage of the Fund's investments will be components of the reference benchmark. However, their weightings may deviate materially from those of the reference benchmark.
- Income is distributed.
- You may sell your investment on most working days.
- Recommendation: this Fund may not be appropriate for investors who plan to withdraw their money within a period of 5 years.

Risk and Reward Profile



The risk and reward indicator is based on historical data and may not be a reliable indication of the future risk profile of the Fund. The risk and reward category shown is not guaranteed to remain unchanged and may shift over time. The lowest category does not mean a risk-free investment.

Why is this Fund in this specific category?

This Fund is classified in category 6 because its price or simulated data has shown high fluctuations historically.

Material risks not fully captured by the Risk and Reward Indicator:

Concentration Risk The Fund may be concentrated in a limited number of securities, economic sectors and/or countries. As a result, it may be

- more volatile and have a greater risk of loss than more broadly diversified
- Counterparty Risk The possibility that the counterparty to a transaction
- may be unwilling or unable to meet its obligations. **Exchange Rate Risk** Changes in currency exchange rates could reduce or increase investment gains or investment losses, in some cases
- Investment Leverage Risk Investment Leverage occurs when the economic exposure is greater than the amount invested, such as when derivatives are used. A Fund that employs leverage may experience greater gains and/or losses due to the amplification effect from a movement in the price of the reference source. **Liquidity Risk** Liquidity Risk is the risk that a Fund may encounter
- difficulties meeting its obligations in respect of financial liabilities that are settled by delivering cash or other financial assets, thereby
- compromising existing or remaining investors. **Operational Risk** Operational risks may subject the Fund to errors affecting transactions, valuation, accounting, and financial reporting, among other things.

Charges

The charges you pay are used to pay the running costs of the Fund, including the marketing and distribution costs. These charges reduce the potential growth of the investment.

Entry charge 5.00% Exit charge 0.00%	One-off charges taken before or after you invest	
Exit charge 0.00%	Entry charge	5.00%
	Exit charge	0.00%


This is the maximum that might be taken out of your money before it is invested or before the proceeds of your investment are paid out.

it is invested or before the proceeds of your inve	stment are paid out.
Charges taken from the Fund over a year	
Ongoing charge	0.70%
Charges taken from the Fund under certain	specific conditions
Performance fee	None

- The entry and exit charges shown are the maximum that may be charged. In some cases you may pay less. You can obtain the actual charges from your financial adviser.
- A conversion charge of up to 1.00% of the Net Asset Value of the Shares which are being converted may be payable to the relevant distributor.
- The ongoing charges figure shown here is an estimate of the charges as the share class has not been priced for a full financial year. The UCITS' annual report for each financial year will include detail on the exact charges made.

Further information on Charges can be found in the "Charges and Expenses" section of the Fund's Prospectus.

Past Performance



- Past performance is not a guide to future performance; the value of your investment and any income from it can go down as well as up.
- Performance returns are based on the net asset value with distributable income reinvested. Past performance takes account of all ongoing charges but not entry, exit or conversion charges.
- The past performance of this share class is calculated in EUR.
- The reference benchmark for the Fund, for comparison purposes only, is the MSCI World Health Care Index (USD).
- The Fund was launched on 28 July 2021.

Practical Information

Depositary Bank

HSBC Continental Europe, Luxembourg.

Further information

Further information about the Company including the Prospectus, the most recent annual and semi-annual reports of the Company and the latest share prices, may be obtained free of charge, in English, from the Registrar and Transfer Agent by emailing amgtransferagency@lu.hsbc.com, or by visiting www.global.assetmanagement.hsbc.com. The most recent Prospectus is available in English and German.

This document describes a single share class of a sub-fund of the Company. The Prospectus, annual and semi-annual reports are prepared for the entire Company.

Share classes

It is possible to switch your shares into shares of a different share class or sub-fund within the Company. Details of how to do this are in the "How to convert between Sub-Funds / Classes" section of the Prospectus.

Remuneration Policy

The up-to-date remuneration policy of the Management Company, including a description of how remuneration and benefits are determined, is available

at www.global.assetmanagement.hsbc.com/about-us/ governance-structure. A paper copy is available free of charge from the Management Company.

Tax

The Fund is subject to Luxembourg tax regulations. This may have an impact on your personal tax position.

Management Company

HSBC Investment Funds (Luxembourg) S.A. may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the Prospectus.

Segregated liability

HSBC Global Investment Funds is an investment company ("Société d'Investissementà Capital Variable") with segregated liability between subfunds under Luxembourg law. This means that the holdings of one sub-fund are kept separate from the holdings of the other sub-funds and your investment in the Fund cannot be used to pay the liabilities of any other subfund.

The Fund is authorised in the Grand Duchy of Luxembourg and supervised by the Commission de Surveillance du Secteur Financier (CSSF). This key investor information is accurate as at 08 February 2024.